Literature DB >> 29600258

Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes.

Rachel L Denlinger1, Tracy T Smith2, Sharon E Murphy3, Joseph S Koopmeiners4, Neal L Benowitz5, Dorothy K Hatsukami6, Lauren R Pacek7, Cirielle Colino8, Samantha N Cwalina9, Eric C Donny10.   

Abstract

OBJECTIVES: Research using very low nicotine content (VLNC) cigarettes has shown that participants underreport use of non-study cigarettes. Biomarkers of nicotine exposure could be used to verify compliance with VLNC cigarettes. This study aimed to characterize biomarkers of exposure when participants exclusively use VLNC cigarettes.
METHODS: 23 participants stayed in a hotel that permitted smoking for 5 days and 4 nights. They were provided 2 packs of VLNC cigarettes each day (0.4 mg of nicotine/g of tobacco; Spectrum cigarettes) and did not have access to other tobacco products. 24-hour urine samples were collected to assess exposure to nicotine and anatabine.
RESULTS: After 4 days of exclusive use, the geometric means for urinary total cotinine, total nicotine equivalents (TNE), and anatabine were 1.13 nmol/ml (92% reduction), 3.17 nmol/ml (94% reduction) and 0.0031 nmol/ml (93% reduction). The population estimates of the 95th percentile of cotinine, TNE, and anatabine levels were 2.69, 6.41, and 0.0099 nmol/ml, respectively.
CONCLUSIONS: Study participants exclusively smoking 0.4 mg/g Spectrum cigarettes are unlikely to have biomarker values above these levels. The data presented here will be valuable to researchers conducting research on use of VLNC cigarettes.

Entities:  

Keywords:  VLNC cigarettes; anatabine; biomarkers; cotinine; nicotine reduction; total nicotine equivalents

Year:  2016        PMID: 29600258      PMCID: PMC5870904          DOI: 10.18001/TRS.2.2.9

Source DB:  PubMed          Journal:  Tob Regul Sci        ISSN: 2333-9748


  25 in total

1.  Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings.

Authors:  L S Cox; S T Tiffany; A G Christen
Journal:  Nicotine Tob Res       Date:  2001-02       Impact factor: 4.244

2.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

3.  Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure.

Authors:  M J Jarvis; M A Russell; N L Benowitz; C Feyerabend
Journal:  Am J Public Health       Date:  1988-06       Impact factor: 9.308

4.  Dose-response effects of spectrum research cigarettes.

Authors:  Dorothy K Hatsukami; Stephen J Heishman; Rachel Isaksson Vogel; Rachel L Denlinger; Astia N Roper-Batker; Kristen M Mackowick; Joni Jensen; Sharon E Murphy; Brian F Thomas; Eric Donny
Journal:  Nicotine Tob Res       Date:  2012-11-22       Impact factor: 4.244

5.  Establishing a nicotine threshold for addiction. The implications for tobacco regulation.

Authors:  N L Benowitz; J E Henningfield
Journal:  N Engl J Med       Date:  1994-07-14       Impact factor: 91.245

6.  Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.

Authors:  Neal L Benowitz; Katherine M Dains; Sharon M Hall; Susan Stewart; Margaret Wilson; Delia Dempsey; Peyton Jacob
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-21       Impact factor: 4.254

7.  The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.

Authors:  Andy Z X Zhu; Caroline C Renner; Dorothy K Hatsukami; Gary E Swan; Caryn Lerman; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-31       Impact factor: 4.254

8.  Application of GC-MS/MS for the analysis of tobacco alkaloids in cigarette filler and various tobacco species.

Authors:  Joseph G Lisko; Stephen B Stanfill; Bryce W Duncan; Clifford H Watson
Journal:  Anal Chem       Date:  2013-02-27       Impact factor: 6.986

9.  Greater reductions in nicotine exposure while smoking very low nicotine content cigarettes predict smoking cessation.

Authors:  Sarah S Dermody; Eric C Donny; Louise A Hertsgaard; Dorothy K Hatsukami
Journal:  Tob Control       Date:  2014-09-05       Impact factor: 7.552

Review 10.  Chemical evaluation of electronic cigarettes.

Authors:  Tianrong Cheng
Journal:  Tob Control       Date:  2014-05       Impact factor: 7.552

View more
  15 in total

1.  Young adult dual combusted cigarette and e-cigarette users' anticipated responses to a nicotine reduction policy and menthol ban in combusted cigarettes.

Authors:  Lauren R Pacek; Jason A Oliver; Maggie M Sweitzer; F Joseph McClernon
Journal:  Drug Alcohol Depend       Date:  2018-10-26       Impact factor: 4.492

2.  Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.

Authors:  Jeffrey A Boatman; David M Vock; Joseph S Koopmeiners; Eric C Donny
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

3.  Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.

Authors:  Dorothy K Hatsukami; Xianghua Luo; Joni A Jensen; Mustafa al'Absi; Sharon S Allen; Steven G Carmella; Menglan Chen; Paul M Cinciripini; Rachel Denlinger-Apte; David J Drobes; Joseph S Koopmeiners; Tonya Lane; Chap T Le; Scott Leischow; Kai Luo; F Joseph McClernon; Sharon E Murphy; Viviana Paiano; Jason D Robinson; Herbert Severson; Christopher Sipe; Andrew A Strasser; Lori G Strayer; Mei Kuen Tang; Ryan Vandrey; Stephen S Hecht; Neal L Benowitz; Eric C Donny
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

4.  The Impact of Exclusive Use of Very Low Nicotine Cigarettes on Compensatory Smoking: An Inpatient Crossover Clinical Trial.

Authors:  Eric C Donny; Matthew J Carpenter; Tracy T Smith; Joseph S Koopmeiners; Cassidy M White; Rachel L Denlinger-Apte; Lauren R Pacek; Víctor R De Jesús; Lanqing Wang; Clifford Watson; Benjamin C Blount; Dorothy K Hatsukami; Neal L Benowitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-26       Impact factor: 4.254

5.  A fully Bayesian mixture model approach for identifying noncompliance in a regulatory tobacco clinical trial.

Authors:  Alexander M Kaizer; Joseph S Koopmeiners
Journal:  Stat Med       Date:  2020-01-21       Impact factor: 2.373

6.  Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes.

Authors:  Rachel L Denlinger-Apte; Jennifer W Tidey; Joseph S Koopmeiners; Dorothy K Hatsukami; Tracy T Smith; Lauren R Pacek; F Joseph McClernon; Eric C Donny
Journal:  Tob Control       Date:  2018-11-01       Impact factor: 7.552

7.  Efficiency and robustness of causal effect estimators when noncompliance is measured with error.

Authors:  Jeffrey A Boatman; David M Vock; Joseph S Koopmeiners
Journal:  Stat Med       Date:  2018-08-14       Impact factor: 2.373

8.  Impact of nicotine reduction in cigarettes on smoking behavior and exposure: Are there differences by race/ethnicity, educational attainment, or gender?

Authors:  Dana M Carroll; Bruce R Lindgren; Sarah S Dermody; Rachel Denlinger-Apte; Andrew Egbert; Rachel N Cassidy; Tracy T Smith; Lauren R Pacek; Alicia M Allen; Jennifer W Tidey; Michael J Parks; Joseph S Koopmeiners; Eric C Donny; Dorothy K Hatsukami
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852

9.  "I actually finally feel like the cigarettes aren't controlling me." - Interviews with participants smoking very low nicotine content cigarettes during a residential study.

Authors:  Rachel L Denlinger-Apte; Cassidy M White; Eric C Donny; Dorothy K Hatsukami; Neal L Benowitz; Matthew J Carpenter; Tracy T Smith
Journal:  Drug Alcohol Depend       Date:  2020-12-19       Impact factor: 4.492

10.  Detecting participant noncompliance across multiple time points by modeling a longitudinal biomarker.

Authors:  Ross L Peterson; Joseph S Koopmeiners; Tracy T Smith; Sharon E Murphy; Eric C Donny; David M Vock
Journal:  Clin Trials       Date:  2020-09-14       Impact factor: 2.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.